

## Appendix 4E Preliminary final report

Rule 4.3A  
Introduced 1/1/2003

Name of Entity: Chrysos Corporation Limited  
ABN: 76 613 131 141

1. Reporting period ("current period"): Year ended 30 June 2022  
Previous corresponding period: Year ended 30 June 2021

**2. Results for announcement to the market:**

				<b>\$A'000</b>
Revenue	up	210%	to	14,258
Profit / (loss) from ordinary activities after tax attributable to shareholders	down	2%	to	(3,938)
Net profit / (loss) for the period attributable to shareholders	down	2%	to	(3,938)

Dividends	Amount per share cents	Franked amount per share cents
Final	-	-
Interim	-	-

Record date for determining entitlements to dividends: N/A

Brief explanation of figures 2.1 to 2.4 (if necessary):  
N/A

**3. Condensed consolidated income statement**

	Current Period	Previous corresponding period
	\$A'000	\$A'000
PhotonAssay™ Income	13,521	4,388
Revenue from Consumables	571	-
Other Income	166	142
Maintenance Costs	(1,840)	(786)
Employee benefit expenses	(6,712)	(3,695)
Consulting fees	(261)	(40)
Consumables cost of sales	(542)	-
Travel and marketing costs	(656)	(259)
Legal fees	(400)	(176)
Other Expenses	(1,685)	(605)
Depreciation and amortisation expense	(2,825)	(2,343)
Finance Costs	(1,905)	(468)
<b>Profit / (loss) before income tax expense</b>	<b>(2,568)</b>	<b>(3,842)</b>
Income tax expense	(1,370)	-
<b>Profit / (loss) from continuing operations</b>	<b>(3,938)</b>	<b>(3,842)</b>
Profit / (loss) from discontinued operations	-	-
<b>Profit / (loss) for the period</b>	<b>(3,938)</b>	<b>(3,842)</b>
Net profit / (loss) attributable to minority interest	-	-
<b>Profit / (loss) attributable to shareholders of the parent entity</b>	<b>(3,938)</b>	<b>(3,842)</b>
Revenue & Other Income		
PhotonAssay™ Income		
PhotonAssay™ Income – minimum lease payments	10,592	4,228
PhotonAssay™ Income – variable lease payments	2,928	160
	<b>13,521</b>	<b>4,388</b>
Revenue from consumables	571	-
Other Income		
Government Grants	70	86
Gains / (losses) on foreign currency	-	(6)
Interest	96	62
	<b>166</b>	<b>142</b>

Expenses:

Loss before income tax includes the following specific expenses:

Depreciation		
Plant & Equipment	80	42
Deployed Units	2,405	1,880
	<b>2,485</b>	<b>1,922</b>
Right of use assets	137	71
	<b>2,622</b>	<b>1,993</b>
Amortisation		
Intellectual Property	203	350
	<b>203</b>	<b>350</b>
<b>Total Depreciation and Amortisation</b>	<b>2,825</b>	<b>2,343</b>
Finance Costs		
Interest and finance charges paid/payable on other liabilities	613	461
Interest and finance charges paid/payable on lease liabilities	1,716	5
(Gains)/Losses on Foreign Exchange	(424)	-
<b>Finance costs expensed</b>	<b>1,905</b>	<b>468</b>
Short term lease payments	26	14
Superannuation on defined contribution funds	515	290

**4. Condensed Consolidated balance sheet:**

	Current Period	Previous corresponding period
	\$A'000	\$A'000
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	92,104	5,768
Trade and other receivables	5,782	1,024
Research & development receivable	872	957
Other Current assets	715	44
Prepayments	5,235	2,119
<b>TOTAL CURRENT ASSETS</b>	<b>104,708</b>	<b>9,912</b>
<b>NON-CURRENT ASSETS</b>		
Property, Plant & Equipment	37,861	18,775
Right of use assets	139	130
Intangible assets	1,378	695
<b>TOTAL NON-CURRENT ASSETS</b>	<b>39,378</b>	<b>19,600</b>
<b>TOTAL ASSETS</b>	<b>144,086</b>	<b>29,512</b>
<b>CURRENT LIABILITIES</b>		
Trade and other payables	10,098	7,706
Lease liabilities	141	136
Employee benefits	734	573
Other financial liabilities	436	358
Provisions	1,395	1,194
<b>TOTAL CURRENT LIABILITIES</b>	<b>12,804</b>	<b>9,967</b>
<b>NON-CURRENT LIABILITIES</b>		
Trade and other payables	623	2,489
Employee benefits	98	27
Other financial liabilities	3,343	2,647
Provisions	-	154
Loans and Borrowings	4,900	-
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>8,964</b>	<b>5,317</b>
<b>TOTAL LIABILITIES</b>	<b>21,768</b>	<b>15,284</b>
<b>NET ASSETS</b>	<b>122,318</b>	<b>14,228</b>
<b>EQUITY</b>		
Issued Capital	135,725	24,081
Other reserves	(14,527)	(10,589)
Accumulated losses	1,120	736
<b>TOTAL EQUITY</b>	<b>122,318</b>	<b>14,228</b>

**5. Condensed consolidated statement of cash flows**

	<b>Current Period</b>	<b>Previous corresponding period</b>
	<b>\$A'000</b>	<b>\$A'000</b>
Net Cash flows from operating activities		
Receipts from customers (inclusive of GST)	12,319	4,479
Payments to suppliers & employees (inclusive of GST)	(11,496)	(4,928)
Research and development refund received	957	1,186
Interest paid	(373)	(186)
<b>Net cash provided / (used in) operating activities</b>	<b>1,407</b>	<b>551</b>
Cash flows from investing activities		
Interest received	96	62
Purchases of intangibles	(1,561)	(973)
Purchases of property, plant and equipment	(25,515)	(7,100)
<b>Net cash provided / (used in) investing activities</b>	<b>(26,980)</b>	<b>(8,011)</b>
Cash flows from financing activities		
Proceeds from issue of share capital	113,194	-
Transaction costs of issue of share capital	(5,136)	-
Proceeds from loan borrowings	4,900	-
Repayment of lease liabilities	(145)	(72)
Repayment of other borrowings	(1,294)	(196)
<b>Net cash provided / (used in) financing activities</b>	<b>111,519</b>	<b>(268)</b>
Net increase / (decrease) in cash & cash equivalents	(85,946)	(7,728)
<b>Cash &amp; cash equivalents at the beginning of the financial period</b>	<b>5,768</b>	<b>13,496</b>
Effects of exchange rate changes on the balance of cash & cash equivalents in foreign currencies	390	-
<b>Cash &amp; cash equivalents at the end of the financial period</b>	<b>92,104</b>	<b>5,768</b>

**6. Dividends**

		Amount per security	Franked amount per security at 30% tax	Amount per security of foreign source dividend
		Cents	Cents	Cents
Final Dividend	Current year	-	-	-
	Previous year	-	-	-
Interim Dividend	Current year	-	-	-
	Previous year	-	-	-

**Total Dividends on all securities for the year**

	Current period	Previous corresponding period
Ordinary securities	98,125,214	75,695,122
Preference securities	-	-
Other equity instruments	-	-
Total	98,125,214	75,695,122

**7. Dividend reinvestment plans**

The dividend reinvestment plans shown below are in operation:

None

Last date for receipt of election notices for the dividend reinvestment plan: N/A

**8. Retained Earnings**

	Current period	Previous corresponding period
	\$'000	\$'000
(Accumulated Losses) at beginning of financial period	(10,589)	(6,747)
Net / (loss) attributable to members	(3,938)	(3,842)
(Accumulated Losses) at end of financial period	(14,527)	(10,589)

**9. Net Tangible Assets**

	Current period	Previous corresponding period
	\$	\$
Net tangible asset backing per ordinary share	1.23	0.05

#### 10. Details of entities which control has been gained or lost

Chrysos Corporation Limited has the following 100% wholly owned subsidiaries in which were incorporated during the financial period:

- Chrysos International Holdings Pty Ltd (Incorporated in Australia and on 27 October 2021)
- Chrysos AU Operations Pty Ltd (Incorporated in Australia and on 8 June 2022)
- Chrysos CA Holdings Ltd (Incorporated in Canada and on 21 November 2021)
- Chrysos CA Operations Ltd (Incorporated in Canada and on 21 November 2021)
- Chrysos Operations Ltd (Incorporated in Tanzania and on 23 February 2022)
- Chrysos EST Pty Ltd ATF Chrysos EST Trust (Incorporated in Australia and on 6 April 2022)
- Chrysos Africa Pty Ltd (Incorporated in Australia and on 12 May 2022)

#### 11. Details of associates and joint venture entities

N/A

#### 12. Any other significant information

N/A

#### 13. Accounting Standards

The financial report is a general-purpose financial report that has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) other authoritative pronouncements of the Australian Accounting Standards board and the Corporations Act 2001.

#### 14. Results for the period

##### 14.1. Earnings per security

	Current period	Previous corresponding period
	Cents	Cents
Basic earnings per share	(4.5)	(5.1)
Weighted average number of ordinary shares outstanding during the period used in the calculation of basic EPS	Number 86,593,409	Number 75,695,122

##### 14.2. Returns to shareholders

N/A

##### 14.3. Significant features of operating performances

Continued growth due to deployment of PhotonAssay™ Max Units.

**14.4. Segment Results**

	<b>Current period</b>	<b>Previous corresponding period</b>
	<b>\$'000</b>	<b>\$'000</b>
Segment Revenues		
Australia	12,006	4,341
Middle East & Africa	2,188	-
Americas	64	-
<b>Total Revenues</b>	<b>14,258</b>	<b>4,341</b>
Segment Depreciation & Amortisation		
Australia	2,157	1,841
Middle East & Africa	264	-
Americas	64	-
<b>Total of segments Depreciation &amp; Amortisation</b>	<b>2,485</b>	<b>1,841</b>
Segment Results: Profit before tax		
Australia	7,172	3,159
Middle East & Africa	1,591	-
Americas	(66)	-
<b>Total of segments</b>	<b>8,698</b>	<b>3,159</b>
Reconciliation of reportable segment to profit / (loss) before tax		
Segment profit	8,698	3,159
Central Costs	(11,266)	(7,001)
<b>Profit / (Loss) before tax</b>	<b>(3,337)</b>	<b>(3,842)</b>
Income tax benefit / (expense)	(1,370)	-
<b>Comprehensive profit / (loss) for the period</b>	<b>(3,938)</b>	<b>(3,842)</b>
Segment Capital Expenditure		
Australia	14,326	10,708
Middle East & Africa	3,595	-
Americas	3,722	-

	<b>Assets</b>		<b>Liabilities</b>	
	<b>Current period</b>	<b>Previous corresponding period</b>	<b>Current period</b>	<b>Previous corresponding period</b>
	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>
Australia - Current	3,667	1,023	7,001	11,303
Australia – Total	17,463	17,498	7,001	11,303
Middle East & Africa – Current	2,187	-	-	-
Middle East & Africa – Total	5,518	-	-	-
Americas – Current	3,722	-	-	-
Americas – Total	3,722	-	-	-
<b>Total of Segments</b>	<b>26,703</b>	<b>17,498</b>	<b>7,001</b>	<b>11,303</b>
Unallocated	117,383	12,014	14,769	3,981
<b>Total</b>	<b>144,086</b>	<b>29,512</b>	<b>21,770</b>	<b>15,284</b>



**14.5. Trends in performance**

Performance in line with the prospectus forecast. Revenue and EBITDA outperformed prospectus.

- 14.6. Any other factors which have affected the results in the period which are likely to affect the result in the future, including those where the effect could not be quantified

N/A

**15. This report is based on accounts to which one of the following applies**

- The accounts have been audited
- The accounts have been subject to review
- The accounts are in the process of being audited or subject to review
- The accounts have not been audited or reviewed

16. Description of any likely audit dispute or qualification

N/A

Sign here:

  
Company Director  
Dirk Moore Treasure

Date: 29 August 2022